VLA15 Vaccine for Lyme Disease

This trial tests the safety and effectiveness of a Lyme disease vaccine called VLA15 after participants receive a fifth dose. It compares the experiences of those who receive the vaccine with those who receive a simple saline shot. Suitable candidates are generally healthy individuals who have already had four doses of VLA15 and are not currently taking medications like chemotherapy or blood thinners. Participants will visit the clinic four times over about a year to monitor their health and receive the vaccine or saline injection. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially bringing a new vaccine to market.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking medicines like chemotherapy, blood products, or blood thinners.

In a previous study, the Lyme disease vaccine VLA15 showed good safety results. Research indicates that VLA15 was safe and well-tolerated across all age groups. Most side effects were mild or moderate, such as soreness at the injection site or brief tiredness, similar to those of other vaccines. Importantly, no serious reactions were linked to VLA15, and FDA reviews confirmed that the vaccine did not cause any harm. Overall, evidence from previous studies suggests that VLA15 is safe for people.¹²³⁴⁵

Unlike the standard of care for Lyme disease, which typically involves antibiotics like doxycycline or amoxicillin, the VLA15 vaccine offers a preventive approach. Researchers are excited about VLA15 because it targets the outer surface protein A (OspA) on Borrelia burgdorferi, the bacteria responsible for Lyme disease, creating an immune response before the infection can occur. This vaccine is delivered as an intramuscular injection, aiming to provide long-lasting immunity. By preventing the disease rather than treating it after infection, VLA15 could significantly reduce the incidence of Lyme disease, making it a groundbreaking addition to current options.

Research has shown that the VLA15 vaccine holds promise in preventing Lyme disease. One study found it to be over 70% effective in individuals aged five and older. VLA15 targets several types of bacteria that cause Lyme disease. Testing has confirmed its safety, with most side effects being mild or moderate. Early results suggest that a booster dose can help maintain high antibody levels. Antibodies are proteins that help fight infections. This trial will evaluate different timings for the booster dose of VLA15, with some participants receiving it one year after their fourth dose and others two years after. This vaccine is currently the only one in development specifically for Lyme disease, marking a significant step forward in prevention efforts.¹³⁵⁶⁷